Trials / Completed
CompletedNCT00185042
Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Coronary Artery Disease
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of the ACAT Inhibitor CS-505 for Reducing the Progression of Atherosclerosis in Subjects With Coronary Artery Disease Using Intravascular Ultrasound (IVUS)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 534 (actual)
- Sponsor
- Daiichi Sankyo · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to learn if CS-505 is safe and effective for slowing down or possibly reversing the buildup of tissue, cells and fatty deposits (plaque) in the blood vessels of the heart (coronary artery atherosclerosis).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pactimibe, CS-505 |
Timeline
- Start date
- 2002-11-01
- Completion
- 2005-07-01
- First posted
- 2005-09-16
- Last updated
- 2007-09-11
Locations
46 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00185042. Inclusion in this directory is not an endorsement.